Non-static framework for understanding adaptive designs: an ethical justification in paediatric trials
Many drugs used in paediatric medicine are off-label. There is a rising call for the use of adaptive clinical trial designs (ADs) in responding to the need for safe and effective drugs given their potential to offer efficiency and cost-effective benefits compared with traditional clinical trials. AD...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| Published: |
2022
|
| In: |
Journal of medical ethics
Year: 2022, Volume: 48, Issue: 11, Pages: 825-831 |
| Online Access: |
Volltext (kostenfrei) Volltext (kostenfrei) |
MARC
| LEADER | 00000naa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1918655383 | ||
| 003 | DE-627 | ||
| 005 | 20250226154951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/medethics-2021-107263 |2 doi | |
| 035 | |a (DE-627)1918655383 | ||
| 035 | |a (DE-599)KXP1918655383 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Afolabi, Michael OS |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Non-static framework for understanding adaptive designs: an ethical justification in paediatric trials |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Many drugs used in paediatric medicine are off-label. There is a rising call for the use of adaptive clinical trial designs (ADs) in responding to the need for safe and effective drugs given their potential to offer efficiency and cost-effective benefits compared with traditional clinical trials. ADs have a strong appeal in paediatric clinical trials given the small number of available participants, limited understanding of age-related variability and the desire to limit exposure to futile or unsafe interventions. Although the ethical value of adaptive trials has increasingly come under scrutiny, there is a paucity of literature on the ethical dilemmas that may be associated with paediatric adaptive designs (PADs). This paper highlights some of these ethical concerns around safety, scientific/social value and caregiver/guardian comprehension of the trial design. Against this background, the paper develops a non-static conceptual lens for understanding PADs. It shows that ADs are epistemically open and reduce some of the knowledge-associated uncertainties inherent in clinical trials as well as fast-track the time to draw conclusions about the value of evaluated drugs/treatments. On this note, the authors argue that PADs are ethically justifiable given they (1) have multiple layers of safety, exposing enrolled children to lesser potential risks, (2) create social/scientific value generally and for paediatric populations in particular, (3) specifically foster the flourishing of paediatric populations and (4) can significantly improve paediatric trial efficiency when properly designed and implemented. However, because PADs are relatively new and their regulatory, ethical and logistical characteristics are yet to be clarified in some jurisdictions, the cooperation of various public and private stakeholders is required to ensure that the interests of children, their caregivers and parents/guardians are best served while exposing paediatric research subjects to the most minimal of risks when they are enrolled in paediatric trials that use ADs. | ||
| 700 | 1 | |a Kelly, Lauren E. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical ethics |d London : BMJ Publ., 1975 |g 48(2022), 11, Seite 825-831 |h Online-Ressource |w (DE-627)323607802 |w (DE-600)2026397-1 |w (DE-576)260773972 |x 1473-4257 |7 nnas |
| 773 | 1 | 8 | |g volume:48 |g year:2022 |g number:11 |g pages:825-831 |
| 856 | |u https://jme.bmj.com/content/medethics/early/2021/09/15/medethics-2021-107263.full.pdf |x unpaywall |z Vermutlich kostenfreier Zugang |h publisher [deprecated] | ||
| 856 | 4 | 0 | |u https://doi.org/10.1136/medethics-2021-107263 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://jme.bmj.com/content/48/11/825 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 467349220X | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1918655383 | ||
| LOK | |0 005 20250226154951 | ||
| LOK | |0 008 250226||||||||||||||||ger||||||| | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixzo |a ixrk | ||
| OAS | |a 1 | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||
